Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of sodium salicylate in treating patients who have advanced myelodysplastic syndrome , acute myelogenous leukemia or chronic lymphocytic leukemia.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
OBJECTIVES:
-
Evaluate the safety, toxicity, and pharmacokinetics of sodium salicylate in patients with advanced myelodysplastic syndrome; newly diagnosed, relapsed, or refractory acute myelogenous leukemia; or relapsed or refractory chronic lymphocytic leukemia.
-
Define biologic characteristics that influence the likelihood of a clinical response to this drug in this patient population.
OUTLINE: Patients receive oral sodium salicylate twice a day. Intrapatient dose escalation or de-escalation is permitted. Treatment continues for up to 6 weeks in the absence of unacceptable toxicity or disease progression. Responding patients may continue to receive sodium salicylate beyond the 6-week period.
Patients with acute myelogenous leukemia are followed until the end of therapy. Patients with myelodysplastic syndrome are followed until death or progression to leukemia.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Relapsed or refractory acute myelogenous leukemia OR
-
Elderly patients with newly diagnosed acute myelogenous leukemia not eligible for standard therapy OR
-
"High-risk" myelodysplastic syndrome, including:
-
Refractory anemia with excess blasts
-
Refractory anemia with excess blasts in transformation
-
Chronic myelomonocytic leukemia OR
-
Relapsed or refractory chronic lymphocytic leukemia
-
Not eligible for transplant protocols at MSKCC or refuses transplant
-
Not eligible for a higher priority protocol (e.g., bone marrow transplantation)
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Platelet count at least 25,000/mm^3
Hepatic:
-
Bilirubin no greater than 2.0 mg/dL
-
Transaminase levels less than 3 times upper limit of normal
-
PT no greater than 14 seconds
-
PTT no greater than 34.6 seconds
Renal:
-
Creatinine no greater than 2.0 mg/dL OR
-
Creatinine clearance greater than 60 mL/min
Other:
-
Not pregnant or nursing
-
No history of abnormal bleeding or unexplained bleeding disorders
-
No history of peptic ulcer disease
-
No salicylate allergy
-
No other concurrent active malignancy
-
No other concurrent illness that would preclude study assessment to a significant degree
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10021 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
Investigators
- Study Chair: Virginia Klimek, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 99-057
- P30CA008748
- MSKCC-99057
- NCI-G99-1661